Directorio

We are doing this study to find out what strategy after surgery has the best outcomes for patients with triple-negative breast cancer who have a complete response to chemotherapy before their surgeries. We want to compare 27 weeks of treatment with pembrolizumab after surgery to 27 weeks of monitoring without drug treatment and find out if there is a difference in terms of risk of having the cancer come back.

We are doing this study to find out if an experimental drug called ORIC-114 (the study drug) is a safe and effective option for possible treatment in patients with advanced solid tumors harboring an EGFR or HER2 alteration.

We are doing this study to improve treatment options for people with opioid use disorder. We want to know if a certain brain signal can better predict how someone will respond to buprenorphine (Suboxone®), and we also want to find out if a non-invasive treatment called repetitive Transcranial Magnetic Stimulation (rTMS) can help people quit opioids more easily than just taking buprenorphine alone. rTMS involves placing a coil against the scalp, and delivers magnetic pulses that stimulate a specific part of the brain. For this study, we will focus on the part of the brain involved with self-control. This procedure is FDA-approved for depression and is commonly used in other addiction treatments (smoking cessation).

We are doing this study to learn more about why some people develop pain syndromes after a stroke. We want to find out if certain brain areas, like the ventral posterior lateral nucleus of the thalamus and its connections, are linked to this pain.

We are doing this study to find out if an experimental drug called LY4066434 (the study drug) is a safe and effective option for patients who have solid tumor(s) with a KRAS mutation. We want to know how well the study drug works on its own and in combination with other anti-cancer therapies.

We are doing this study to evaluate the performance of an experimental medical technology called the Patched Sepsis Prediction Algorithm (the study technology). This technology is designed to detect the early signs of sepsis and give clinicians the chance to treat it earlier than usual.

We are doing this study to find the most effective, safe dose of an experimental drug called pocenbrodib (the study drug). We want to see how it works when it is given by itself and also when it is given with other drugs already approved for the treatment in people with metastatic castration-resistant prostate cancer (mCRPC).

We are doing this study to test a program that is being developed by nurses to help patients with HER2+ metastatic breast cancer manage their treatment with three drugs typically used for this diagnosis: tucatinib, trastuzumab, and capecitabine. The program's goal is to help patients manage symptoms and provide resources to improve their quality of life.